Renal/Urology · PANCE / PANRE

Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Hereditary cystic kidney disease causing progressive enlargement and renal failure by middle age.

Also known as: ADPKD, polycystic kidney disease, PKD, PKD1, PKD2

Overview

An autosomal dominant systemic disorder characterized by progressive development and enlargement of bilateral renal cysts leading to massive nephromegaly and progressive loss of renal function. Caused by mutations in PKD1 (chromosome 16, ~78%) or PKD2 (chromosome 4, ~15%) encoding polycystin-1 and polycystin-2.

Epidemiology

Most common inherited kidney disease, prevalence ~1 in 400-1000. Accounts for ~5% of ESRD. PKD1 mutations cause earlier ESRD (median ~55 years) vs PKD2 (~75 years).

🔒 Free preview limit reached

Keep reading — start your free trial

You've read your 2 free diagnosis previews. Create your free account to unlock the full Autosomal Dominant Polycystic Kidney Disease (ADPKD) outline — plus all 514 diagnoses, 3,500+ board-style questions, flashcards, and an AI tutor. Your 7-day free trial includes everything, and there's no credit card required.

Start your 7-day free trial → Sign in

Free to start · No credit card · Cancel anytime

Risk factors

Family history of ADPKD (positive in ~85%; spontaneous mutations ~15%)
Male sex (faster progression)
Hypertension before age 35 (accelerates decline)
Larger total kidney volume (height-adjusted; Mayo classification A-E)
PKD1 truncating mutation (worst prognosis)

Pathophysiology

Defective polycystin proteins disrupt primary cilia signaling in tubular epithelial cells. Loss of heterozygosity (somatic 'second hit') triggers focal cystogenesis from any nephron segment. Cysts expand via cAMP-driven fluid secretion and epithelial proliferation, compressing adjacent parenchyma, distorting vascular architecture, and progressively reducing functional nephron mass.

Clinical presentation

Symptoms

Often asymptomatic until 3rd-4th decade
Flank or abdominal pain (cyst hemorrhage, infection, or stone)
Gross hematuria (cyst rupture into collecting system)
Recurrent UTIs, cyst infections
Headache (hypertension or intracranial aneurysm)
Early satiety, abdominal fullness from massive nephromegaly

Signs / physical exam

Hypertension (often the first manifestation, may precede cyst formation on imaging)
Palpable enlarged kidneys (bilateral abdominal masses)
Hepatic cysts in 80% by age 60 (rarely cause dysfunction)
Mitral valve prolapse murmur, aortic regurgitation
Inguinal or umbilical hernia

Classic findings

Hypertensive young adult with bilateral flank pain, hematuria, and family history of kidney disease.

Differential diagnosis

Autosomal recessive PKD (ARPKD) — Presents in infancy/childhood; ductal plate malformation with congenital hepatic fibrosis; PKHD1 mutation
Simple renal cysts — Common with age, unilateral or few; no family history; normal kidney size and function
Acquired cystic kidney disease — Develops in ESRD patients on dialysis; small shrunken kidneys with cysts
Medullary sponge kidney — Cystic dilation of collecting ducts; recurrent stones, UTIs; 'paintbrush' on IVP
Tuberous sclerosis complex — Cysts + angiomyolipomas + neurocutaneous findings (ash leaf, shagreen patch); TSC1/TSC2 mutations
Von Hippel-Lindau — Cysts + renal cell carcinoma + hemangioblastomas + pheochromocytoma

Diagnostic workup

Diagnostic criteria

Modified Ravine ultrasound criteria for at-risk individuals: Age 15-39: ≥3 cysts (unilateral or bilateral). Age 40-59: ≥2 cysts in each kidney. Age ≥60: ≥4 cysts in each kidney. Absence of criteria in PKD1 family >40 yr essentially excludes disease.

Labs

BMP — eGFR may be preserved well into adulthood
Urinalysis — hematuria during cyst hemorrhage; mild proteinuria
Lipid panel, A1c for cardiovascular risk
Genetic testing (PKD1, PKD2, GANAB) — confirms diagnosis when imaging equivocal or for early pre-symptomatic diagnosis

Imaging

Renal ultrasound — first-line screening; modified Ravine criteria diagnose ADPKD based on age and cyst number
MRI or CT — better characterization, total kidney volume (TKV) measurement for prognosis (Mayo classification)
MR angiography for screening intracranial aneurysm in patients with family history of aneurysm/SAH or high-risk occupation

Diagnostic algorithm

Feature	ADPKD	ARPKD
Inheritance	Autosomal dominant	Autosomal recessive
Gene	PKD1 (~78%), PKD2 (~15%)	PKHD1 (fibrocystin)
Typical presentation age	3rd-4th decade adult	Infancy/childhood
Kidney appearance	Large cysts of varying sizes, bilateral	Diffuse small cysts, ductal pattern
Hepatic involvement	Hepatic cysts (asymptomatic usually)	Congenital hepatic fibrosis, portal HTN
Extra-renal	Aneurysms, MVP, diverticula, hernias	Pulmonary hypoplasia (neonatal)
Prognosis	ESRD median 55 (PKD1) / 75 (PKD2)	30-50% mortality in 1st year; 70% survival to 15 yr

Comparison of ADPKD and ARPKD — inheritance, presentation, and prognosis.

Treatment

First-line

Aggressive BP control — target <120/75 in CKD stages 1-2 (HALT-PKD); ACEi (lisinopril, ramipril, enalapril) or ARB (losartan, valsartan, irbesartan) first-line
Tolvaptan — vasopressin V2 receptor antagonist; FDA-approved for adults at risk of rapid progression (eGFR 25-65, evidence of progression, Mayo class 1C-1E); slows eGFR decline and TKV growth
High water intake (>2.5-3 L/day) to suppress vasopressin (theoretical benefit; recommended outside tolvaptan)
Low sodium diet, normal protein intake, weight control
Statin if dyslipidemia or CVD risk; avoid nephrotoxins

Second-line / adjunct

Pain management: avoid chronic NSAIDs; acetaminophen, tramadol; cyst aspiration/sclerosis for refractory pain
Cyst infection: lipophilic antibiotics (fluoroquinolones — ciprofloxacin, levofloxacin; trimethoprim-sulfamethoxazole) for ≥4-6 weeks; drainage if no response
Stones: management as for general urolithiasis; alpha-blocker, hydration, surgical removal as needed
Aneurysm screening: MRA in patients with family history of intracranial aneurysm or SAH; treat aneurysms >7 mm or symptomatic
RRT/transplant for ESRD — transplant outcomes equivalent to general population; native nephrectomy may be needed pre-transplant if massive nephromegaly

Complications

Hypertension (often early, before significant CKD)
Progressive CKD/ESRD by 4th-7th decade
Intracranial aneurysms (5-10%, higher with family history); subarachnoid hemorrhage
Cyst hemorrhage, infection, stones
Hepatic cysts (rarely symptomatic), pancreatic and seminal vesicle cysts
Cardiovascular: mitral valve prolapse, aortic regurgitation, aortic root dilation
Diverticulosis, abdominal/inguinal hernias
Increased risk of renal cell carcinoma (modest)

PANCE pearls

Hypertension often precedes detectable cysts on imaging and is the earliest clinical manifestation.
Mayo Clinic imaging classification (A-E) uses height-adjusted total kidney volume + age to predict progression and identify tolvaptan candidates.
Tolvaptan side effects: polyuria (vasopressin antagonism), hepatotoxicity (monthly LFT monitoring for first 18 months mandatory).
Screen for intracranial aneurysm with MRA if family history of aneurysm or SAH, high-risk occupation (pilot), or prior to major elective surgery.
Avoid NSAIDs (nephrotoxic) and chronic anticoagulation when possible (cyst hemorrhage and SAH risk).
Genetic counseling and reproductive options (preimplantation genetic diagnosis) for affected families.

References

KDIGO 2024 — KDIGO Clinical Practice Guideline for ADPKD: 2024 Update
HALT-PKD — Blood-Pressure Targets in Patients with ADPKD (Schrier et al., NEJM 2014)
TEMPO 3:4 — Tolvaptan in Patients with ADPKD (Torres et al., NEJM 2012)
REPRISE — Tolvaptan in Later-Stage ADPKD (Torres et al., NEJM 2017)

Practice Renal/Urology questions on FirstPassPA

Turn this outline into retention. 3,500+ board-style questions with an AI tutor that explains every answer — free to start, no card required.

Start studying free → Browse all 514 diagnoses

Educational use only. This outline is a study aid for PA students and is not medical advice or a substitute for clinical judgment. FirstPassPA is an independent study tool and is not affiliated with, endorsed by, or sponsored by NCCPA. PANCE® and PANRE® are registered trademarks of the National Commission on Certification of Physician Assistants.